Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.57 |
| ▸ | WNT3A | P56704 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | DDX3X | O00571 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16102541 | 0.87 | NPC1 (0.63) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16102824 | 0.84 | RAB9A (0.62) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16101701 | 0.84 | RAB9A (0.62) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16102177 | 0.84 | RAB9A (0.62) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16101372 | 0.83 | NPC1 (0.55) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16102178 | 0.81 | WNT3A (0.58) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16101712 | 0.81 | NPC1 (0.67) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16101666 | 0.81 | RAB9A (0.61) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL11480689 | 0.79 | CSNK2A2 (0.83) | NPC1RAB9AKDM4ESMN1; SMN2CSNK2A2 | |
| SCHEMBL16102875 | 0.79 | WNT3A (0.60) | NPC1RAB9AKDM4ESMN1; SMN2WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10130633-B2 | Compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-20 | — | — | US | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| EP-2976327-A2 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | NPC1 184/4885RAB9A 2147/4885KDM4E 2232/4885 |
| US-10130633-B2 | Compounds | AADAC, NAT1, CBR3 | NPC1 215/4885RAB9A 2650/4885KDM4E 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.